{
    "nct_id": "NCT05250895",
    "official_title": "Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttirum-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma- Pilot Study",
    "inclusion_criteria": "* Age >= 18 years\n* Established HCC diagnosis, unilobar or bilobar disease\n* At least 1 tumor >= 3 cm\n* Oligometastatic disease\n* Barcelona Clinic Liver Cancer (BCLC) stage A, B or C\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\n* Life expectancy > 12 weeks as determined by the Investigator\n* The effects of Y90 Radioembolization on the developing human fetus are unknown. For this reason, female of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy\n* FCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who are definite transplant candidates\n* Concurrent second malignancy outside of the liver\n* Infiltrative liver tumor\n* Previous liver-directed therapy to targeted tumors\n* BCLC stage D\n* Bilirubin > 2 mg/dL for lobar treatment and bilirubin > 3 mg/dL for segmental or bi-segmental Y90-SIRT\n* Albumin < 3 g/dL\n* Projected lung dose of > 30 Gy in a single session to the liver after prospective treatment planning\n* Body mass index (BMI) > 40",
    "miscellaneous_criteria": ""
}